Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 32, 2023 - Issue 1
Submit an article Journal homepage
1,400
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Cardiac myosin inhibitors for hypertrophic cardiomyopathy: shedding light on their clinical potential

Shiavax J Raoa Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USAORCID Iconhttps://orcid.org/0000-0002-7724-2089View further author information
ORCID Icon,
Beani Forstb Department of Medicine, Creighton University Arizona Health Education Alliance, Phoenix, Az, USAView further author information
,
Amreen K Kanwalc Tufts University School of Medicine, Boston, MA, USAView further author information
,
Arjun Kanwald Department of Cardiology, Westchester Medical Center, Valhalla, NY, USAORCID Iconhttps://orcid.org/0000-0002-6370-289XView further author information
ORCID Icon,
Wilbert S. Aronowe Department of Cardiology, Westchester Medical Center and Department of Medicine, New York Medical College, Valhalla, NY, USACorrespondence[email protected]
View further author information
&
Srihari S Naiduf Hypertrophic Cardiomyopathy Center, Cardiac Catheterization Laboratory, Department of Cardiology, Westchester Medical Center and Department of Medicine, New York Medical College, Valhalla, NY, USAView further author information
Pages 1-4 | Received 27 Sep 2022, Accepted 06 Jan 2023, Published online: 12 Jan 2023

References

  • Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2020 Dec 22;142:e558–631
  • Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014 Oct 14;35(39): 2733–2779.
  • Direct Sarcomere TO. Modulators are promising new treatments for cardiomyopathies. Int J Mol Sci. 2019 Dec;28(21):226.
  • Ariga R, Tunnicliffe EM, Manohar SG, et al. Identification of myocardial disarray in patients with hypertrophic cardiomyopathy and ventricular arrhythmias. J Am Coll Cardiol. 2019 May;28(73):2493–2502.
  • Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006 Nov;21(114):2232–2239.
  • Marian AJ, Hypertrophic Cardiomyopathy BE, Genetics P, et al. Diagnosis, and therapy. Circ Res. 2017 Sep;15(121):749–770.
  • Kim LK, Swaminathan RV, Looser P, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003-2011. JAMA Cardiol. 2016 Jun 1;1(3):324–332.
  • Rohde JA, Roopnarine O, Thomas DD, et al. Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin. Proc Natl Acad Sci U S A. 2018 Aug;7(115):E7486–94.
  • Lekaditi D, Myosin Modulators SS. The new era of medical therapy for systolic heart failure and hypertrophic cardiomyopathy. Cardiol Res. 2021 Jun;12(3):146–148.
  • Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med. 2019 Jun;4(170):741–748.
  • Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020 Jun;2(75):2649–2660.
  • Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2020 Sep 12;396(10253):759–769.
  • Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022 Jul;80(2):95–108.
  • Tamargo J, Tamargo M, Caballero R. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline. Expert Opin Investig Drugs. 2022 Oct;3(31):1027–1052.
  • Chuang C, Collibee S, Ashcraft L, et al. Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem. 2021 Oct 14;64(19):14142–14152.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.